Chronic Fatigue in Testicular Cancer Survivors

A. Torstveit¹, A. A. Dahl¹, S. D. Fosså¹, I. Utne² Oslo University Hospital (1), Oslo and Akershus University College of Applied Science (2)

INTRODUCTION

- Testicular cancer survivors are at risk of chronic fatigue (CF) as a result from cancer and cancer treatment.
- CF is described as one of the most troublesome and common long-term symptom among cancer survivors.
- CF is often reported to have a negative effect on quality of life.

PURPOSE

The aims of this study in a sample of testicular cancer survivors are:

- To describe the level of CF in 1998 2002 (T1) (mean 11 years after diagnosis).
- To describe the level of CF in 2007- 2008 (T2) (mean 8 years after T1), and
- To investigate changes in level of CF from T1 to T2

MATERIALS & METHODS

INCLUSION CRITERIA

- Men aged 18-75 years treated for unilateral germ cell TC in Norway (1980-1994).
- <60 years at T1.</p>
- Completed Fatigue Questionnaire at T1 and T2.

INSTRUMENTS

- Demographic questionnaire.
- Fatigue Questionnaire.

DATA ANALYSIS


- Descriptive statistics were generated for demographic and clinical characteristics.
- Chi-squared test were used to investigate changes in level of CF from T1 to T2.

RESULTS

Table 1: Demografic and clinical characteristics in testicular cancer survivors at T1.

| Characteristics, N = 934 | N (%) |
|--------------------------|------------|
| Partnered relations | 712 (76) |
| Years of education > 13 | 350 (38) |
| Currently working | 861 (93) |
| Economic problems | 109 (12) |
| | Mean (SD) |
| Age at T1, years | 42.7 (7.8) |
| Age at diagnosis, years | 31.3 (7.5) |
| Follow-up time, years | 11.3 (4.1) |

Diagram 1: Changes in Chronic Fatigue from T1 to T2



Chronic Fatigue in 1998 16,0 % (95 % Cl 14,7 % - 19,5 %) Chronic Fatigue in 1998 16,0 % (95 % Cl 1,6 % - 18,3 %) Chronic Fatigue in 2007 28,4 % (95 % Cl 25,5 % - 31,3 %) Significance of the distributions i 1998 og 2007 p < 0,001

CONCLUSIONS

• A significant number of TCSs report CF many years after treatment.

• This study shows a significant increase in CF between T1 and T2





OSLO AND AKERSHUS UNIVERSITY COLLEGE OF APPLIED SCIENCES